"New National System: Cooperation between Government and Enterprise" 2020 China Antiviral Drug Innovation Conference Held in Suzhou

!---- On July 11, 2020, under the support of the China Pharmaceutical Biotechnology Association and the China Pharmaceutical Enterprise Management Association, the "2020 China Antiviral Drug Innovation Conference" was organized by the People's Government of Suzhou Xiangcheng City, the People's Government of Huangxuan Town, Suzhou City, the Suzhou City Development and Reform Committee, the Suzhou Xiangcheng Health Committee, the E-drug manager, and the 50-person Forum on Investment in China's Medical and Health IndustryChinese Academy of Engineering academicians Yu Daiming, Zhang Boli, Li, The Chief Epidemiology Scientist of the Chinese Center for Disease Control and Prevention Zeng Guang and other experts and scholars attended the meeting and delivered keynote speeches in a combination of online and offlineis understood to be attending the conference with more than 200 scientists, entrepreneurs and investors from the medical and health sectorfor a long time, humans have been fighting the virus relentlesslyfrom smallpox and hepatitis, to AIDS, SARS, MERS, and the new coronaviruses of the moment, humans have been working to develop vaccines to prevent them or to suppress thembut the unique structure and proliferation of viruses, so that drug research and development face natural challenges, especially to deal with sudden infectious diseases, in the short term to develop a vaccine or find special drugs more difficultfacing the challenge, since the 11th Five-Year Plan, China has clearly proposed to take biopharmaceutical innovation, build a number of major disease prevention and control vaccines and genetic engineering drug industrialization demonstration project, enhance independent innovation ability as a national strategic goalrecently, General Secretary Xi Jinping has once again proposed to strengthen scientific and technological innovation and emergency response capacity from an institutional mechanism, speed up the construction of a new national system of key core technologies, make up for the short board, strengthen and weak items, close loopholes, and enhance the systematization capacity of scientific and technological innovation, the development of antiviral drugs (vaccines) in China has also begun to enter a new stage of developmentIn this context, the, the 2020 China Antiviral Drug Innovation Conference was used, and took the opportunity to bring together government authorities, experts and scholars, as well as representatives of production, learning, research and capital, to explore innovative models for research and development of antiviral drugs and vaccines with Chinese characteristicsAt the beginning of theconference, Li, a member of the Chinese Academy of Engineering, president of Wenzhou Medical University and president of the Virus Research Institute, Guo Yunpei, honorary president of the China Pharmaceutical Enterprise Management Association, chairman of the China Pharmaceutical Biotechnology Association, chairman and president of Cinda Biopharmaceutical Group, delivered a speechIn his speech,Guo Yunpei pointed out that under the epidemic, research and development and innovation of antiviral drugs/vaccines have received more extensive attention, global research and development innovation institutions are accelerating, we can only make greater contributions to human health through collaborative innovationin his speech,Yu Dechao said that drug innovation should not only have research and development investment, personnel support, more crucial is to through this outbreak, so that China's medical and health system mechanism has been a fundamental improvement at a time when the global epidemic has not been effectively controlled, Professor Zeng Guang analyzed the trend trend of global epidemic development around the theme of "Global New Crown Epidemic Study and The Next China Epidemic Prevention Strategy" and also put forward a constructive strategy for the next stage of epidemic prevention in China , academicians Yu Daiming and Zhang Boli, communicated with the audience from the medical development after the epidemic and the advantages and characteristics of Chinese medicine anti-epidemic and from Tsinghua University Cross School of Medicine, the director of the International Bioeconomy Center, the Ministry of Science and Technology, China Biotechnology Development Center, the former director of wang Hongguang from the top-level design perspective on how to provide institutional support for epidemic prevention and control, scientific and technological support made a keynote speech , the conference also invited Wang Gang, chief scientist of the life sciences and pharmaceutical division of Corey Weian, a world-renowned pharmaceutical innovation service, and Wu Jinxuan, chairman and chief executive officer of Clarite Pharmaceuticals and part-time researcher of the new drug industry at the Shanghai Institute of Pharmaceutical Research of the Chinese Academy of Sciences, respectively, on the "Global Antiviral Drug Research Panorama and Future Trends Outlook" and "Top-level Design of China's Antiviral Drug Research: Lessons and Lessons from the New Crown Epidemic." it is worth mentioning that the special "antiviral drugs / vaccine research progress release" link of the conference, from Jiangsu Province CDC, Shandong University Medicine, Shanghai Medicine, Kangsino Biology and other 8 research institutions, pharmaceutical enterprises respectively disclosed their progress in anti-neo-coronavirus drugs and vaccine research and development At the end of the conference, two round-table discussions were held on the theme of "improving the national anti-epidemic drugs/vaccine research and supply assurance system, how to better play the role of enterprises" and "how to break the barriers in the face of the virus pandemic, production, learning, research and capital" and "how to achieve effective sharing cooperation" , Global Vice President of Gilead Sciences, General Manager of China, Luo Yongqing, Chairman of Frontier Biology Xie Dong, Director of the Center for Global Public Health of the China Center for Disease Control and Prevention Dong Xiaoping, Director of the Second Affiliated Hospital of Chongqing Medical University Ren Hong, And Hong Tan, Managing Director of Junlian Capital, participated in the discussion also briefed the participants on the basic situation and industrial development policies of Xiangcheng BiopharmaceuticalSa, and held a ceremony to unveil the china Pharmaceutical Enterprise Management Association and the Suzhou Xiangcheng Pharmaceutical Industry Innovation Cooperation Platform Source: E Drug Manager's !-- Content Presentation Ends -- !-- Determine signed-up